Case ReportJournal of Pharmacology and PharmacotherapeuticsVol. 10 | Issue 1 | 2019 | pp. 42–44Open access
Subconjunctival Bevacizumab for Recurrent Conjunctival Pyogenic Granuloma
- 1*,
- 1,
- 1,
- 2
- 1 Department of Ophthalmology, Jawaharlal Postgraduate Medical Education and Research, Puducherry, India.
- 2 Department of Pathology, Jawaharlal Postgraduate Medical Education and Research, Puducherry, India.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Nirupama Kasturi
Department of Ophthalmology, Jawaharlal Postgraduate Medical Education and Research, Puducherry, India.
Email: kasturiniru@gmail.com
Copyright: © 2019 Manuscript Technomedia LLP. This is an open access article.
- Published:
- Jan 1, 2019
- Received:
- Nov 3, 2018
- Accepted:
- Apr 1, 2019
How to cite
Kasturi, N., Senthamizh, T., Bheemanathi, H. S., & Babu, K. R. (2019). Subconjunctival Bevacizumab for Recurrent Conjunctival Pyogenic Granuloma. Journal of Pharmacology and Pharmacotherapeutics, 10(1), 42–44. https://doi.org/10.4103/jpp.JPP_123_18
Abstract
A 45-year-old male presented with a pyogenic granuloma of the bulbar conjunctiva of the left eye following a stick injury. It was a benign friable, hyperplastic, vascular lesion comprised of inflammatory cells and lobular capillary proliferation. The differential diagnosis includes squamous papillomas, hemangiomas, suture granulomas, and ocular surface tumors, such as squamous cell carcinoma and amelanotic melanoma. Conventional treatment includes topical corticosteroids and surgical excision. Treatment of recurrent lesions with cryotherapy, electrocautery, topical antimetabolites, and plaque irradiation has been described. We present a case of recurrent pyogenic granuloma successfully treated with two subconjunctival bevacizumab injections. The patient developed three recurrences after excision at a peripheral hospital after which he was successfully treated with excision and adjuvant subconjunctival bevacizumab 2.5 mg/0.1 ml injection. This case highlights the novel use of bevacizumab for recurrent pyogenic granuloma.
Keywords
Subject
Article metadata
| Title | Subconjunctival Bevacizumab for Recurrent Conjunctival Pyogenic Granuloma |
|---|---|
| Authors | Nirupama Kasturi; Tharini Senthamizh; Hanuman Srinivas Bheemanathi; K. Ramesh Babu |
| Affiliations | Department of Ophthalmology, Jawaharlal Postgraduate Medical Education and Research, Puducherry, India.; Department of Pathology, Jawaharlal Postgraduate Medical Education and Research, Puducherry, India. |
| Corresponding author | kasturiniru@gmail.com |
| Journal | Journal of Pharmacology and Pharmacotherapeutics |
| Volume / Issue | Vol. 10, Issue 1 (2019) |
Also in this issue
- Structural Genomics in Drug Discovery: An Overviewpp. 1–6
- Genotype and Allele Frequency of P450 Oxidoreductase *28 Gene Polymorphism in South Indian Populationpp. 7–10
- Comparison of Safety and Efficacy of Dexmedetomidine versus Propofol Sedation for Elective Awake Fiber-optic Intubationpp. 11–15
- Antidepressants Modulate Behavioral, Biochemical, and Histological Alterations Induced by Chronic Aluminum Chloride Administration in Wistar Ratspp. 16–21
- Pharmacokinetic Modeling of Propofol in Indian Childrenpp. 22–32
Readers Also Viewed
Effect of the Fractions of Coccinia grandis on Ethanol- Induced Cerebral Oxidative Stress in Rats
M. Umamaheswari, T. K. Chatterjee
Jan 1, 2009
Phytochemical Screening and Antioxidant Activity Evaluation of Selected Philippine Fruit Peels and Pulps
Mildred Dagcuta Pates, Angelo Mark Po Walag, Romeo M. Del Rosario
Aug 17, 2026
Impact of Artificial Intelligence Assisted Drug Therapy Optimization on Drug Related Problems Amongst Older Adult Patients: A Systematic Review
Jehath Syed, Christy Thomas, Bavneet Kaur
Oct 23, 2026